The AQOAT trademark has been registered in Australia as a trademark with the Australia Intellectual Property Office. It has been assigned a Trademark Application Number (TAN) 447344, which is a unique identifier that uniquely identifies this trademark in IP Australia. This article will examine the kinetic models and Dissolution profiles of aqoat.
kinetic models of aqoat
Dissolution of enteric-coated aqoat pellets was determined using enteric-coated pellets with different enteric polymers. Enteric-coated pellets with a 30% increase in weight gained greater dissolution rate. These pellets were also significantly more soluble in NH3.
The chemistry of aqoat is similar to that of other sugars and fatty acids, but they differ in some ways. These similarities and differences make it an ideal dietary fiber for many applications. Aqoat has several properties that make it an excellent cleansing agent.
Aqoat is an enteric-coated pellet with a combination of acetyl and succinoyl groups that are compatible with other oral bioactives. The enteric-coated pellets were manufactured using a fluidized-bed processor. They were tested in vitro for their physical and dissolution profiles. Aqoat AS-LF was compared with HPMCP HP-55 and Eudragit L30D55.
Enteric-coating weight gain
For a successful enteric-coating formulation, the enteric polymer should be applied as an aqueous solution. This is important because the enteric polymer, such as Aqoat(r) AS-LF, is insoluble in water, whereas ammonium is soluble. Hence, the enteric-coated pellets with NH3 were disintegrated more slowly than those with a low enteric weight. However, when the enteric weight was increased by 30%, the dissolution rate of the enteric coated pellets was over 50 %, indicating that the enteric coating increased the dissolution rate of the pellets.
The weight gain of three different enteric-coated formulations was investigated. Among them, Eudragit(r) L30D55 showed the highest gain (35%) and Aqoat(r) AS-LF the least. Both of these formulations showed similarity factors (f2) higher than 50. SEM images of Eudragit(r) L30D54 and Aqoat(r) ASLF showed smooth surfaces during 0 day and a hazy surface after one month at 40 degC/75% relative humidity.
As the enteric-coating weight gain increased, the amount of duloxetine released in the acidic medium decreased. In fact, the amount of duloxetine released was completely restrained when the enteric-coated pellets reached 12% or 15%. Further, the enteric-coated pellets had a low fluid uptake, requiring less fluid for disintegration.
To assess the dissolution profiles of Aqoat, we prepared pellets from the drug substance using two-layered membrane techniques. These methods use a centrifugal granulator to prepare the pellets and a fluidized bed coater to prepare the coating. The prepared pellets were assessed physicochemically and compared to a reference formulation.
Enteric-coated pellets were tested for their ability to release duloxetine in an acidic medium. As enteric coatings were applied in increasing amounts, the percentage of duloxetine released in acidic medium decreased. The lowest enteric-coated weight of pellets was 10%. The best formulation was 24% enteric-coated duloxetine.
Pellets formulated with Aqoat-AS-LF had a lower dissolution rate. Similarly, pellets coated with NH3 showed a lower dissolution rate than those coated with uncoated pellets. However, pellets with 30% enteric weight gained significantly increased the dissolution rate. Furthermore, the dissolution rate was higher when f2 was greater than 50 g/l.